Ontology highlight
ABSTRACT:
SUBMITTER: Alumkal JJ
PROVIDER: S-EPMC7275746 | biostudies-literature | 2020 Jun
REPOSITORIES: biostudies-literature
Alumkal Joshi J JJ Sun Duanchen D Lu Eric E Beer Tomasz M TM Thomas George V GV Latour Emile E Aggarwal Rahul R Cetnar Jeremy J Ryan Charles J CJ Tabatabaei Shaadi S Bailey Shawna S Turina Claire B CB Quigley David A DA Guan Xiangnan X Foye Adam A Youngren Jack F JF Urrutia Joshua J Huang Jiaoti J Weinstein Alana S AS Friedl Verena V Rettig Matthew M Reiter Robert E RE Spratt Daniel E DE Gleave Martin M Evans Christopher P CP Stuart Joshua M JM Chen Yiyi Y Feng Felix Y FY Small Eric J EJ Witte Owen N ON Xia Zheng Z
Proceedings of the National Academy of Sciences of the United States of America 20200518 22
The androgen receptor (AR) antagonist enzalutamide is one of the principal treatments for men with castration-resistant prostate cancer (CRPC). However, not all patients respond, and resistance mechanisms are largely unknown. We hypothesized that genomic and transcriptional features from metastatic CRPC biopsies prior to treatment would be predictive of de novo treatment resistance. To this end, we conducted a phase II trial of enzalutamide treatment (160 mg/d) in 36 men with metastatic CRPC. Th ...[more]